文献速递肝病

抗凝治疗对肝硬化门静脉血栓的临床影响与安全性

Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

该研究分析2008年1月至2016年3月间182例肝硬化合并门静脉血栓且随访至少3个月的患者,其中81例接受抗凝治疗、101例未治疗。抗凝组血栓范围缩小超过50%者46例(56.8%,其中31/46完全再通),未治疗组26例(25.7%);

要点

  • 抗凝组46例(56.8%)血栓缩小超过50%,其中31/46完全再通,未治疗组为26例(25.7%)。
  • 46例再通患者中17例(36%)在停用抗凝后出现血栓复发。

核心结论

  • 作者认为抗凝治疗安全有效,可使56.8%的病例实现门静脉系统部分或完全再通,并改善肝硬化合并门静脉血栓患者的生存;停药与较高的门静脉血栓复发率相关。

研究设计与样本

  • 研究分析了2008年1月至2016年3月间182例肝硬化合并门静脉血栓、首次检出后随访至少3个月的患者资料;81例接受抗凝治疗,101例由医生酌情未治疗。

主要发现

  • 抗凝组46例(56.8%,其中31/46完全再通)血栓范围缩小超过50%,未治疗组26例(25.7%)缩小超过50%。
  • 46例再通患者中17例(36%)在停用抗凝后出现血栓复发。
  • Kaplan-Meier分析显示治疗组生存率更高(P=0.010)。
  • 出血并发症发生于未治疗组22例(21.8%)与治疗组16例(19.7%),仅4例判定与抗凝治疗相关,无出血事件导致死亡的报告。

临床怎么用

  • 作者认为抗凝治疗是安全有效的治疗,可使56.8%的病例实现门静脉系统部分或完全再通并改善生存;作者指出停药与较高的门静脉血栓复发率相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Portal vein thrombosis (PVT) is a frequent complication of cirrhosis. Benefit, safety, and duration of anticoagulant treatment in this setting are controversial issues. The aim of this study was to analyze the course of PVT in a large cohort of cirrhotic patients undergoing or not anticoagulation therapy. METHODS: The data of 182 patients who presented between January 2008 and March 2016 with cirrhosis and PVT with at least 3 months of follow-up after the first PVT detection were analyzed. Eighty-one patients received anticoagulants and 101 were untreated per physician discretion. RESULTS: The extension of the thrombosis decreased by >50% in 46 (56.8%, with complete recanalization in 31/46) patients under anticoagulation and in 26 (25.7%) untreated patients. Of the 46 patients who underwent recanalization, 17 (36%) suffered recurrent thrombosis after stopping anticoagulation therapy. Kaplan-Meier analysis showed a higher survival rate in the treated group (p = 0.010). At multivariate analysis, anticoagulation was an independent factor associated with longer survival (HR:0.30, CI:0.10-0.91, p = 0.014). The Child-Turcotte-Pugh classes B/C negatively influenced survival (hazard ratio, (HR):3.09, confidence interval (CI):1.14-8.36, p = 0.027 for Child-Turcotte-Pugh B and HR:9.27, CI:2.67-32.23, p < 0.001 for Child-Turcotte-Pugh C). Bleeding complications occurred in 22 (21.8%) untreated and 16 (19.7%) treated patients, but in only four cases was it judged to be related to the anticoagulant treatment. No death was reported as a consequence of the bleeding events. CONCLUSIONS: Anticoagulant treatment is a safe and effective treatment leading to partial or complete recanalization of the portal venous system in 56.8% of cases, improving the survival of patients with cirrhosis and PVT. Discontinuation of the therapy is associated with a high rate of PVT recurrence.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Pettinari I, Vukotic R, Stefanescu H, et al. Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol. 2019. PMID: 30538290. doi:10.1038/s41395-018-0421-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。